 |
第52巻第7号目次 | Japanese/English |
 | Full Text of PDF (323K) Article in Japanese |
─ 原著 ─
Efficacy and Tolerability of the Bevacizumab/carboplatin/paclitaxel Combination Therapy as First-line or Non-first-line Therapy for Non-small-cell Lung Cancer
Makoto Nakashima1,2, Ryoko Ohnishi3, Mizuho Kobayashi3, Toshitaka Suzuki3, Shigeo Yasuda3, Kimiyasu Sano3, Takuya Goto1, Nobuyuki Mishima1, Tatsuo Kato3, Tadashi Sugiyama21Department of Pharmacy, Nagara Medical Center, Japan, 2Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Japan, 3Department of Respiratory Medicine, Nagara Medical Center, Japan
Objective. Bevacizumab/carboplatin/paclitaxel (BEV-CP) combination therapy extends the progression-free survival (PFS) of chemotherapy-naive patients with non-small-cell lung cancer. However, the efficacy and tolerability of BEV-CP therapy in patients with a history of chemotherapy have not been investigated. In the present study, patients receiving BEV-CP therapy at the Nagara Medical Center were divided into 2 groups. Methods. The first-line therapy (FLT) group consisted of 18 patients who had never received chemotherapy before treatment with BEV-CP, and the non-FLT group included 13 patients who had received other chemotherapy regimens before BEV-CP therapy. The efficacy and tolerability of BEV-CP therapy in the FLT and non-FLT groups were analyzed retrospectively. Results. The response rate (RR) was 72.2% in the FLT group and 61.5% in the non-FLT group, whereas the disease control rate (DCR) was 83.3% in the FLT group and 92.3% in the non-FLT group. However, neither RR nor DCR was statistically significant between the FLT and non-FLT groups (p=0.40 and 0.43, respectively). The median PFS time was 240 days in the FLT group and 258 days in the non-FLT group, which was not statistically significant (p=0.84). The rate of discontinuation of BEV-CP therapy because of adverse effects was 22.2% in the FLT group and 7.7% in the non-FLT group. The discontinuation rate was lower in the non-FLT group than in the FLT group, but the difference was not statistically significant (p=0.28). Conclusion. The efficacy and tolerability of BEV-CP therapy as non-FLT and FLT were comparable.
索引用語：Non-small-cell lung cancer, Bevacizumab, Second-line therapy, Carboplatin/paclitaxel combination therapy
受付日：2012年4月26日
受理日：2012年11月5日
肺癌 52 (7)：1007─1016，2012
